000078341 001__ 78341
000078341 005__ 20200217133051.0
000078341 0247_ $$2doi$$a10.1016/j.drudis.2018.01.031
000078341 0248_ $$2sideral$$a105480
000078341 037__ $$aART-2018-105480
000078341 041__ $$aeng
000078341 100__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini, E.$$uUniversidad de Zaragoza
000078341 245__ $$aIncreasing mtDNA levels as therapy for mitochondrial optic neuropathies
000078341 260__ $$c2018
000078341 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078341 5203_ $$aLeber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma (POAG) is a frequent, acquired optic neuropathy. Lowering intraocular pressure (IOP) reduces disease progression. However, current methods to decelerate this progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic approaches. The growing evidence indicates that POAG can also be a mitochondrial optic neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial (mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation (OXPHOS) capability, and mitochondrial energy production as treatments for MONs.
000078341 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B33$$9info:eu-repo/grantAgreement/ES/DGA/FEDER$$9info:eu-repo/grantAgreement/ES/ISCIII/PI14-00070$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-00021$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-00166$$9info:eu-repo/grantAgreement/ES/ISCIII/P114-00005
000078341 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000078341 590__ $$a6.88$$b2018
000078341 591__ $$aPHARMACOLOGY & PHARMACY$$b12 / 266 = 0.045$$c2018$$dQ1$$eT1
000078341 592__ $$a2.248$$b2018
000078341 593__ $$aPharmacology$$c2018$$dQ1
000078341 593__ $$aDrug Discovery$$c2018$$dQ1
000078341 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000078341 700__ $$0(orcid)0000-0001-5964-6138$$aEmperador, S.$$uUniversidad de Zaragoza
000078341 700__ $$0(orcid)0000-0002-3217-1424$$aLópez-Gallardo, E.$$uUniversidad de Zaragoza
000078341 700__ $$0(orcid)0000-0003-3524-5158$$aHernández-Ainsa, C.$$uUniversidad de Zaragoza
000078341 700__ $$0(orcid)0000-0003-1770-6299$$aMontoya, J.$$uUniversidad de Zaragoza
000078341 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000078341 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000078341 773__ $$g23, 3 (2018), 493-498$$pDrug discov. today$$tDRUG DISCOVERY TODAY$$x1359-6446
000078341 8564_ $$s420347$$uhttps://zaguan.unizar.es/record/78341/files/texto_completo.pdf$$yPostprint
000078341 8564_ $$s43759$$uhttps://zaguan.unizar.es/record/78341/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000078341 909CO $$ooai:zaguan.unizar.es:78341$$particulos$$pdriver
000078341 951__ $$a2020-02-17-12:42:55
000078341 980__ $$aARTICLE